Arrowhead Pharmaceuticals Hits New 52-Week High of $43.69

Arrowhead Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 43.69 on October 31, 2025. This achievement marks a remarkable performance for the small-cap company, which operates within the Pharmaceuticals & Biotechnology industry. Over the past year, Arrowhead Pharmaceuticals has demonstrated a robust growth trajectory, with a performance increase of 72.95%, significantly outpacing the S&P 500's gain of 19.89%.
With a market capitalization of USD 3,756 million, Arrowhead Pharmaceuticals continues to navigate the competitive landscape of its industry. Despite its current loss-making status, indicated by a negative price-to-earnings ratio, the company maintains a price-to-book ratio of 7.19. Additionally, its debt-to-equity ratio stands at -0.56, reflecting a unique financial structure. The company's return on equity is reported at -30.51%, highlighting the challenges it faces in generating profits. As Arrowhead Pharmaceuticals celebrates this new high, it underscores the dynamic nature of the biotechnology sector and the potential for continued developments in the field.